Cannabis PharmaDrug’s Sairiyo Therapeutics Offers Strategic Solutions for Advancing PD-001 (Patented Reformulated Cepharanthine) in Treatment of Viral Infectious DiseasesBy Alexander LeeAugust 28, 20240 On August 28, 2024, PharmaDrug Inc., a specialty pharmaceutical company focused on the research, development, and commercialization of controlled substances…
Cannabis Sairiyo Therapeutics, a subsidiary of PharmaDrug, Announces Independent Screening Identifying Cepharanthine’s Potential Binding to Monkeypox (Mpox) Proteins.By Alexander LeeAugust 21, 20240 August 21, 2024 9:52 AM EDT | Source: PharmaDrug Inc. Toronto, Ontario–(Newsfile Corp. – August 21, 2024) – PharmaDrug…
Cannabis PharmaDrug’s Sairiyo Therapeutics Obtains Approval to Begin Phase 1 Clinical Trial of Patented Reformulated CepharanthineBy Alexander LeeAugust 19, 20240 On August 19, 2024, PharmaDrug Inc. announced that its subsidiary, Sairiyo Therapeutics Inc., has received approval from the Australian Human…
